JD-SW (09618) announced its annual results, reporting a net profit attributable to shareholders of 19.6 billion yuan and a final dividend of $0.50 per share. JD LOGISTICS (02618) released its 2025 annual performance, with a profit attributable to shareholders of 6.647 billion yuan, a year-on-year increase of 7.2%. JD HEALTH (06618) announced annual results, showing a profit attributable to shareholders of 5.375 billion yuan, an increase of 29.16% compared to the previous year. The company launched over 100 new drugs for the first time during the year. JD INDUSTRIALS (07618) reported annual results, with a net profit of 2.314 billion yuan, surging 203.8% year-on-year.

PRADA (01913) disclosed its annual performance, with net revenues of 5.718 billion euros, up 9.1% compared to the prior year. HUTCHMED (00013) announced annual results, recording a profit attributable to shareholders of $457 million, a substantial increase of 1111.03% year-on-year. BILIBILI-W (09626) released its annual performance, achieving an adjusted net profit of 2.59 billion yuan, turning a profit compared to a loss in the previous year. AUTOHOME-S (02518) reported annual results, with a net profit attributable to the parent company of 1.443 billion yuan, and announced a $200 million share repurchase plan.

YIXIN (02858) published its annual results, showing a net profit of 1.199 billion yuan, an increase of 47.98% year-on-year. CTIHK (06055) announced annual results, with a profit attributable to shareholders of HK$980 million, up 14.82% compared to the previous year. Heartcore Group (02400) issued a profit alert, expecting a net profit of no less than 1.58 billion yuan for the 2025 fiscal year, representing an increase of approximately 77.4%.

In major corporate developments, Estun (02715) set its final offer price at HK$15.36 per share. Insilico Medicine (03696) achieved a milestone in its collaboration with TaiGen, with the first subject dosed in the Phase I clinical trial for the externally licensed CKD anemia drug ISM4808. Henlius (02696) received approval from the National Medical Products Administration for the Phase I clinical trial application of HLX97, a KAT6A/B small molecule inhibitor, in patients with advanced/metastatic solid tumors. CanSino Biologics (06185) obtained PIC/S GMP certification.

Fulong Hydrogen (02582) plans to collaborate with BTE and Hylium on a 10-megawatt data center power generation demonstration project in the North American market. Agile Group (03383) intends to sell subsidiary real estate and operating assets to optimize its asset portfolio and address debt risks.